Rgenix begins Phase Ia/b study of RGX-104 to treat cancer

US-based clinical stage bio-pharmaceutical company Rgenix has begun its Phase Ia/b study of RGX-104 to treat advanced solid malignancies and lymphoma.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news